COMMUNITY CONSUMPTION OF ANALGESIC OPIOIDS AND OPIATE SUBSTITUTION TREATMENTS IN A SELF-EMPLOYED WORKERS HEALTH PLAN: TREND, SUBSTITUTION EFFECTS AND DEMOGRAPHIC FACTORS
DOI:
https://doi.org/10.54695/jdds.039.01.6716Keywords:
Opioids prescribing, Opiate substitution treatment, Prescription opioid analgesics, Prescription drug policy, Health insurance, Reimbursement databasesAbstract
Objective: Our aim was to evaluate community consumption of strong prescription opioid treatments in France in 2015 and 2017.
Methods: A nation-wide French health care insurance claims database was analyzed for opioids average annual cost, annual prevalence of dispensations and users by mean of two repeated retrospective cross sectional study in 2015 and 2017.
Results: In 2015–2017 prevalence of users per 100 000 beneficiaries per year rose from 878 to 932 (+6%) for strong opioid analgesics and lowered from 160 to 150 (-6%) for opiate substitution treatments. Prevalence of users of oxycodone, fentanyl, morphine, hydromorphone, buprenorphine, and methadone shifted by +17%, -5%, +4%, -8%, -13%, and +10%, respectively (+20% for methadone capsules). Oxycodone moved from third place to first place in terms of number of dispensation. Highest prevalence were in the western half of France, age over 60 and female for strong analgesic opioids and the north-east quarter and the south-west quarter of France, age 30 to 49 and male for opiate substitution treatments. The factor most strongly associated with prevalence
was age in strong analgesic opioids and gender in opiate substitution treatments.
Conclusions: In 2 years the use of analgesics progresses, especially for oxycodone, while that of the substitution drugs decreases. Despite its greater danger, methadone tends to replace buprenorphine and capsule form tends to replace the syrup. Regulatory changes or enhanced controls may have played a role. The age of strong analgesic opioids consumers highlights the issue of severe pain in the elderly.
References
Beck T, Haasen C, Verthein U, Walcher S, Schuler C, Backmund M, Ruckes C, Reimer J. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction 2014; 109(4): 617-26.
doi:10.1111/add.12440. Epub 2014 Jan 19.
Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol 2011; 71(6):832-43.
doi: 10.1111/j.1365-2125.2011.03923.x.
Cadet-Taïrou A, Gandilhon M. Marchés, substances, usagers : les tendances récentes (2011-2012). Tendances n°86. Observatoire français des drogues et des toxicomanies (Ed). Saint-Denis La Plaine, 2013: 1-8
Nordmann S, Pradel V, Lapeyre-Mestre M, Frauger E, Pauly V, Thirion X, Mallaret M, Jouanjus E, Micallef J. Doctor Shopping Reveals Geographical Variations in Opioid Abuse. Pain Physician 2013; 16: 89-100. ISSN 1533-3159
Lovell A, Aubisson S. « Fuitage pharmaceutique », usages détournés et reconfigurations d’un médicament de substitution aux opiacés. Drogues, santé et société 2008; 7(1) : 297–355 doi:10.7202/019625ar
Bosetti C, Santucci C, Radrezza S, Erthal J, Berterame S, Corli O. Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990-2016. Eur J Pain. 2019; 23 (4): 697-707. doi: 10.1002/ejp.1337. Epub 2018 Dec 4.
Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, Bucher Bartelson B. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med 2012; 13(3): 434-42. doi: 10.1111/j.1526-4637.2012.01327.x. Epub 2012 Feb 2.
Zin CS, Chen LC, Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain 2014; 18: 1343–1351 [9] Chenaf C, Kaboré JL, Delorme J, Pereira B, Mulliez A, Zenut M, Delage N, Ardid D, Eschalier A, Authier N. Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality. Eur J Pain 2019; 23(1):124-134. doi: 10.1002/ejp.1291. Epub 2018 Aug 20.
Couturier S, Potin E, Ledoux L, Cavalié P, Richard N, Inoubli A et al. Consommation des antalgiques opiacés, 2006-2015. Thérapies 2017; 72 (1) : 162. https://doi.org/10.1016/j.therap.2016.11.037
Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol 2018; 84: 1324–1334. DOI:10.11 11/b cp. 13564
Brisacier AC. Tableau de bord « Traitements de substitution aux opiacés » 2018. Observatoire français des drogues et des toxicomanies (Ed). Saint-Denis La Plaine, 2018: 1-17. https://www.ofdt.fr/BDD/publications/docs/TabTSO180206.pdf
Manchikanti L, Helm S, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician 2012; 15(3 Suppl): ES9-38.
Dhalla IA, Mamdani MM, Sivilotti MLA, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009; 181 (12): 891-896. DOI: https://doi.org/10.1503/cmaj.090784
Dupouy J, Palmaro A, Fatséas M, Auriacombe M, Micallef J, Oustric S, Lapeyre-Mestre. Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study. Ann Fam Med 2017; 15: 355-358. https://doi.org/10.1370/afm.2098.
Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry 2015; 2(10): 901-8. doi: 10.1016/S2215-0366(15)00366-1. Epub 2015 Sep 15.
Frauger E, Spadari M, Pochard L, Fouilhé Sam-Laï N, Jouanjus E, Mallaret M, Micallef J. Soyons plus que jamais vigilants avec la méthadone : apport des données d’addictovigilance. Therapies 2018; 73 (6) : 571.
Fischer B, Jones W, Vojtila L, Kurdyak P. Patterns, Changes, and Trends in Prescription Opioid Dispensing in Canada, 2005-2016. Pain Physician 2018; 21(3): 219-228. https://www.ncbi.nlm.nih.gov/pubmed/29871366/
Hollingworth SA, Gray PD, Hall WD, Najman JM. Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiol Drug Saf 2015; 24(6): 628-36. doi: 10.1002/pds.3767. Epub 2015 Apr 1.
Brisacier AC, Collin C. Données récentes relatives aux traitements de substitution aux opiacés - Analyse des données de remboursement concernant l’échantillon généraliste des bénéficiaires en 2011. Observatoire français des drogues et des toxicomanies (Ed). Saint-Denis La Plaine, 2013 : 1-45 https://www.ofdt.fr/BDD/publications/docs/epfxabtb.pdf
Fischer B, Vojtila L, Kurdyak P.’Delisting’ OxyContin® to reduce prescription opioid-related harms in Ontario (Canada)—gauging effects 5 years later. Pharmacoepidemiol Drug Saf. 2017; 26: 1040-1043. https://doi.org/10.1002/pds.4253
Wilquin M, Robinet S. Analyse de la répartition par département des patients recevant un traitement par BHD (Subutex® et ses génériques) et par méthadone en 2011. Le Flyer, Bulletin de liaison des CSST/CSAPA et CAARUD, médecins et pharmaciens d’officine impliqués dans l’accompagnement des usagers de drogues,
services d’addictologie et équipes de liaison et services de soins en milieu pénitentiaire 2012 ; 46 : 4-15. https://www.rvh-synergie.org/images/stories/pdf/flyer_46.pdf
Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol 2016; 30(6): 616-624. doi: 10.1111/fcp.12214. Epub 2016 Jul 13.
Rurup ML, Rhodius CA, Borgsteede SD, Boddaert MS, Keijser AG, Pasman HR, Onwuteaka-Philipsen BD. The use of opioids at the end of life: the knowledge level of Dutch physicians as a potential barrier to effective pain management. BMC Palliat Care 2010; 9: 23. doi: 10.1186/1472-684X-9-23.
Pergolizzi, J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress H, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone). Pain Practice 2008; 8: 287-313.
doi:10.1111/j.1533-2500.2008.00204.
Published
How to Cite
Issue
Section
Copyright (c) 2021 Journal de gestion et d'economie de la santé
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
